NCT02834013 2026-06-03Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting798 enrolled
NCT04065269 2026-02-20ATARIInstitute of Cancer Research, United KingdomPhase 2 Active not recruiting174 enrolled